Phico Therapeutics company

Phico Therapeutics is developing a unique antibiotic technology to address one the most urgent challenges facing medicine today – how to destroy multi-drug resistant bacteria, the so-called “superbugs”.
Phico’s patented platform utilises an antibacterial protein, SASP to inactivate bacterial DNA and cause rapid destruction of target bacteria. SASPject™ is a new class of antibiotic which could provide many advantages over conventional antibiotic classes.
Technology: P4 Medicine
Industry: Personalized Medicine
Headquarters: Cambridge, Cambridgeshire, United Kingdom
Founded Date: 2000
Employees Number: 11-50
Funding Status: N/A
Investors Number: 11
Total Funding: £17.3M
Estimated Revenue: $1M to $10M
Last Funding Type: Grant

Visit Website
info@phicotherapeutics.co.uk
@phicotx
Register and Claim Ownership